Phathom Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 3 months.
- Its last 5 Sell calls were followed by a 8% average decline over the next quarter.
- Recent price momentum is -56.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 11.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation C-
How expensive the stock is versus earnings, sales and its own 5-year history.
| Forward P/E | 99.0x | Better than 3% |
| Price / Sales | 1.8x | Better than 61% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 87.1% | Better than 95% |
| Operating margin | -91.4% | Better than 7% |
| Net margin | -126.3% | Better than 6% |
| Return on equity | -108.0% | Better than 5% |
| Return on invested capital | -67.4% | Better than 4% |
Momentum F
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -47.5% | Better than 6% |
| 6-month return | -58.9% | Better than 5% |
| 12-month return (ex latest month) | -53.3% | Better than 2% |
| Distance below 52-week high | 74.5% | Better than 4% |
Financial Health D-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.7x | Better than 49% |
| Debt to assets | 81.7% | Better than 3% |
| Interest coverage | -2.2x | Better than 20% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 83.3% | Better than 63% |
| Upside to average target | 262.7% | Better than 96% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 5.08
- Open
- 4.93
- Day range
- 4.62 - 5.15
- Avg price
- 4.76
- Volume
- 1.33M
- Turnover
- 6.33M
- Turnover ratei
- 2.02%
- Volume ratioi
- 1.04
- Amplitudei
- 10.43%
- 52-week rangei
- 4.62 - 18.31
Valuation
- P/Ei
- -1.54
- P/E (TTM)i
- -4.61
- P/Bi
- -1.09
- EPSi
- -3.03
- Book value / shi
- -4.28
- Net profit
- -246.31M
- Net assets
- -347.60M
Share structure
- Market cap
- 378.82M
- Float capi
- 307.23M
- Shares out
- 81.29M
- Float sharesi
- 65.93M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-10-25
74.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-6.14M net over the window
Short interest
- Shares short
- 9.20M
- % of floati
- 11.32%
- Days to coveri
- 4.83
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Phathom Pharmaceuticals (PHAT)?
Phathom Pharmaceuticals last traded at 4.66. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Phathom Pharmaceuticals's market cap?
About 378.82M.
What is the P/E ratio of Phathom Pharmaceuticals?
The trailing twelve-month P/E is -4.61. The Valuation tab shows it against the stock's own five-year range.
Does Phathom Pharmaceuticals pay a dividend?
Phathom Pharmaceuticals does not currently pay a regular dividend.
Is Phathom Pharmaceuticals a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 16.90, which implies 262.7% upside from the current price. This is not investment advice.
What is Phathom Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Phathom Pharmaceuticals a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Phathom Pharmaceuticals discussion 0 comments